PAH

IPF/PAH


FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Data Elements


DEMOGRAPHICS

  • Year of Birth
  • Gender
  • Weight
  • Height
  • BMI
  • Ethnicity
  • Race
  • Patient State

DIAGNOSTIC INFORMATION

  • Diagnosis Date
  • ICD 10 Code
  • PAH Symptom Onset Date
  • Etiology

DISPENSE INFORMATION

  • NDC Dispense
  • NDC Product Name
  • Dispense Item Strength
  • Refill Number / Days Supplied
  • Shipment Date

INSURANCE INFORMATION

  • Insurance Type
  • Patient Assistance or Self Pay
  • Copay Amount
  • Out of Pocket Amount
  • Patient Assistance Amount

MEDICAL HISTORY

  • Smoking Status
  • Alcohol Status
  • Illicit Drug Use
  • O2 Therapy Status
  • Transplant Status

COMORBIDITIES

  • Atrial Fibrillation
  • Chronic Kidney Disease
  • Cirrhosis
  • Clinical Depression
  • Connective Tissue Disease
  • COPD
  • CVD/CTD/CAD
  • Diabetes
  • Emphysema
  • Heart Failure – Systolic / Diastolic
  • History of Amiodarone / Cordarone
  • History of Chemotherapy
  • History of Prolonged Use of Furadantin/ Nitrofurantoin/ Macrodantin
  • GERD
  • Hypertension
  • NASH
  • History of Deep Vein Thrombosis
  • History of Pulmonary Embolism
  • Lung Cancer/ Fibrosis
  • Obstructive Sleep Apnea
  • Renal Insufficiency
  • Thyroid Disease
  • Validated History of Asbestos Exposure
  • Valvular Heart Disease
  • Other Cancers
  • Other Liver Diseases

LABS

  • ANA Screen
  • Anti Centromere
  • Anti dsDNA
  • Anti Scl-70
  • Cyclic Citrullinated Peptide
  • RF Factor
  • ECHO
  • VQ Scan
  • White Blood Cells
  • Polymorphonuclear Leukocytes
  • Red Blood Cells
  • Hemoglobin
  • Hematocrit
  • Red Blood Cell Distribution
  • Platelets
  • Serum Creatinine
  • AST
  • ALT
  • eGFR

TESTS

  • Pulmonary Function Test (FEV1, FVC)
  • FEV1/FVC ratio score
  • Diffusing Capacity for Carbon Monoxide (DLCO)
  • Most Recent Walk Test
  • Supplemental Oxygen
  • Lowest SpO2 During Walk
  • Borg Dyspnea Score (Before/ After Walk)
  • Borg Fatigue Score (Before/ After Walk)
  • Thermodilution
  • Right Heart Catheterization Date
  • Distance Walked
  • Max HR During Walk (bpm)
  • Number of Rests
  • Total Rest Time
  • CT Scan
  • CPET
  • BNP
  • NT-proBNP
  • mRAP
  • mPAP
  • PCWP
  • LVEDP
  • Fick
  • Cardiac Index
  • Pulmonary Vascular Resistance
  • Heart Rate
  • RVSP

Scientific Steering Committee


  • Independent Committee to review, approve and author all publications
  • Collaborative approach to develop strategic publication strategy
  • Collaborative workflow, methodology and communication with Trio Analytics and Client
  • Ongoing conference calls and meetings throughout the year
  • Responsive to real-world issues and clinical questions from real-world evidence

Harrison Farber, MD

  • Chairman – IPF/PAH Steering Committee, Trio Health
  • Director, Pulmonary Hypertension Center at Boston Medical Center, Boston, MA
  • Professor of Medicine- Boston University School of Medicine

Murali Chakinala, MD

  • Professor of Medicine, Washington University School of Medicine, St. Louis, MO
  • Director, Pulmonary Hypertension Center, Washington University, St. Louis, MO

Steven Nathan, MD

  • Professor of Medicine at Virginia Commonwealth University
  • Director of the Advanced Lung Disease Program at Inova Fairfax Hospital
  • Director of the Lung Transplant Program at Inova Fairfax Hospital

Robert Frantz, MD

  • Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
  • Director, Pulmonary Hypertension Clinic, Mayo Clinic

Adaani Frost, MD

  • Professor of Medicine, Institute of Academic Medicine, Houston Methodist
  • Former Medical Director of Lung Transplantation – Houston Methodist and developed both PF and IPF centers at the institution

Ronald Oudiz, MD

  • Professor of Medicine, David Geffen School of Medicine – UCLA
  • Director, Liu Center for Pulmonary Hypertension, LA BioMed Research Institute at Harbor – UCLA Medical Center

Lisa Lancaster, MD

  • Associate Professor of Medicine, Vanderbilt University, Nashville, TN
  • Clinical Director, Interstitial Lung Disease Program

Publications


2020


P598 - A Platform to Combine Clinical, Prescription, and Dispensing Data to Better Inform Idiopathic Pulmonary Fibrosis Care; The Trio Registry

S. D. Nathan, M. M. Chakinala, R. P. Frantz, A. E. Frost, L. Lancaster, K. Milligan, S. Milligan, R. J. Oudiz, H. W. Farber; Inova Fairfax Hosp, Falls Church, VA, United States, Washington Univ, Saint Louis, MO, United States, Mayo Clinic, Rochester, MN, United States, Smith Tower, Suite 1001, Houston Methodist Lung Center, Houston, TX, United States, Vanderbilt University School of Medicine, Nashville, TN, United States, Trio Health, La Jolla, CA, United States, Harbor UCLA Med Ctr, Torrance, CA, United States, Tufts Univ Sch of Med, Boston, MA, United States.

Presented at: Session A37 - ILD THERAPY I

Conference dates: January 01, 2020 - January 01, 2020


P1300 - The Trio Pulmonary Arterial Hypertension Registry; a Platform Combining EMR Clinical Measures with Pharmacy Prescription and Dispensing Data

S. D. Nathan, H. W. Farber, M. M. Chakinala, R. P. Frantz, A. E. Frost, S. Milligan6, R. J. Oudiz; Inova Fairfax Hosp, Falls Church, VA, United States, Tufts Univ Sch of Med, Boston, MA, United States, Washington Univ, Saint Louis, MO, United States, Mayo Clinic, Rochester, MN, United States, Smith Tower, Suite 1001, Houston Methodist Lung Center, Houston, TX, United States, Trio Health, La Jolla, CA, United States, Harbor UCLA Med Ctr, Torrance, CA, United States.

Presented at: Session D37 - A PULMONARY AND CRITICAL CARE MEDLEY

Conference dates: January 01, 2020 - January 01, 2020